Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intradermal botulinum toxin vs tranexamic acid for melasma (split-face, randomized double-blind trial)
TCTR20260506004Phase 2Not yet recruiting
- Sponsor
- Phramongkutklao Hospital Foundation
- Start
- May 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of neuronox, tranexamic acid in melasma, sponsored by Phramongkutklao Hospital Foundation. Planned start May 2026; status: not yet recruiting.
02
Drugs
neuronoxtranexamic acid
03
Conditions
melasma
Beyond the preview
Go deeper on TCTR20260506004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260506004.